BridgeBio Pharma, Inc. Operating Income
BridgeBio Pharma, Inc. (BBIO) reported Operating Income of -$107.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- BridgeBio Pharma, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$107.08M.
- BridgeBio Pharma, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$105.96M.
- BridgeBio Pharma, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$139.56M.
- BridgeBio Pharma, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$145.20M.
- BridgeBio Pharma, Inc. operating income (loss) for fiscal 2025 was -$523.41M.
- BridgeBio Pharma, Inc. operating income (loss) for fiscal 2024 was -$592.97M.
- BridgeBio Pharma, Inc. operating income (loss) for fiscal 2023 was -$607.37M.
- BridgeBio Pharma, Inc. operating income (loss) for fiscal 2022 was -$512.20M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$107.08M 10-Q · filed 2026-08-10 | -$213.03M 10-Q · filed 2026-08-10 | -$352.60M derived: sum of 3 quarters · filed 2026-08-10 | -$497.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$105.96M 10-Q · filed 2026-05-07 | -$245.52M derived: sum of 2 quarters · filed 2026-05-07 | -$390.72M derived: sum of 3 quarters · filed 2026-05-07 | -$525.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$139.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$284.76M derived: sum of 2 quarters · filed 2026-02-24 | -$419.04M derived: sum of 3 quarters · filed 2026-08-10 | -$523.41M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$145.20M 10-Q · filed 2025-10-29 | -$279.48M derived: sum of 2 quarters · filed 2026-08-10 | -$383.85M 10-Q · filed 2025-10-29 | -$609.88M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$134.28M 10-Q · filed 2026-08-10 | -$238.65M 10-Q · filed 2026-08-10 | -$464.68M derived: sum of 3 quarters · filed 2026-08-10 | -$656.43M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$104.37M 10-Q · filed 2026-05-07 | -$330.40M derived: sum of 2 quarters · filed 2026-05-07 | -$522.15M derived: sum of 3 quarters · filed 2026-05-07 | -$697.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$226.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$417.78M derived: sum of 2 quarters · filed 2026-02-24 | -$593.32M derived: sum of 3 quarters · filed 2026-02-24 | -$592.97M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$191.75M 10-Q · filed 2025-10-29 | -$367.29M derived: sum of 2 quarters · filed 2025-10-29 | -$366.95M 10-Q · filed 2025-10-29 | -$544.36M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$175.54M 10-Q · filed 2025-08-05 | -$175.20M 10-Q · filed 2025-08-05 | -$352.61M derived: sum of 3 quarters · filed 2026-02-24 | -$510.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $343.00K 10-Q · filed 2025-04-29 | -$177.07M derived: sum of 2 quarters · filed 2026-02-24 | -$334.76M derived: sum of 3 quarters · filed 2026-02-24 | -$480.86M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$177.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$335.11M derived: sum of 2 quarters · filed 2026-02-24 | -$481.21M derived: sum of 3 quarters · filed 2026-02-24 | -$607.37M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$157.69M 10-Q · filed 2024-11-12 | -$303.79M derived: sum of 2 quarters · filed 2024-11-12 | -$429.95M 10-Q · filed 2024-11-12 | -$559.19M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$146.10M 10-Q · filed 2024-08-01 | -$272.26M 10-Q · filed 2024-08-01 | -$401.49M derived: sum of 3 quarters · filed 2025-02-20 | -$530.61M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$126.16M 10-Q · filed 2024-05-02 | -$255.40M derived: sum of 2 quarters · filed 2025-02-20 | -$384.51M derived: sum of 3 quarters · filed 2025-02-20 | -$464.69M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$129.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$258.35M derived: sum of 2 quarters · filed 2025-02-20 | -$338.52M derived: sum of 3 quarters · filed 2025-02-20 | -$512.20M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$129.12M 10-Q · filed 2023-11-02 | -$209.29M derived: sum of 2 quarters · filed 2023-11-02 | -$382.97M 10-Q · filed 2023-11-02 | -$548.58M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$80.18M 10-Q · filed 2023-08-03 | -$253.85M 10-Q · filed 2023-08-03 | -$419.47M derived: sum of 3 quarters · filed 2024-02-22 | -$568.97M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$173.68M 10-Q · filed 2023-05-04 | -$339.29M derived: sum of 2 quarters · filed 2024-02-22 | -$488.79M derived: sum of 3 quarters · filed 2024-02-22 | -$582.81M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$165.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$315.11M derived: sum of 2 quarters · filed 2024-02-22 | -$409.13M derived: sum of 3 quarters · filed 2024-02-22 | -$576.63M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$149.50M 10-Q · filed 2022-11-03 | -$243.51M derived: sum of 2 quarters · filed 2022-11-03 | -$411.02M 10-Q · filed 2022-11-03 | -$538.51M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$94.02M 10-Q · filed 2022-08-04 | -$261.52M 10-Q · filed 2022-08-04 | -$389.01M derived: sum of 3 quarters · filed 2023-02-23 | -$508.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$167.50M 10-Q · filed 2022-05-05 | -$294.99M derived: sum of 2 quarters · filed 2023-02-23 | -$414.93M derived: sum of 3 quarters · filed 2023-02-23 | -$539.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$127.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$247.43M derived: sum of 2 quarters · filed 2023-02-23 | -$372.00M derived: sum of 3 quarters · filed 2023-02-23 | -$474.48M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$119.94M 10-Q · filed 2021-11-04 | -$244.51M derived: sum of 2 quarters · filed 2021-11-04 | -$346.99M 10-Q · filed 2021-11-04 | -$425.63M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$124.57M 10-Q · filed 2021-08-05 | -$227.05M 10-Q · filed 2021-08-05 | -$305.69M derived: sum of 3 quarters · filed 2022-02-25 | -$360.22M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$102.49M 10-Q · filed 2021-05-06 | -$181.13M derived: sum of 2 quarters · filed 2022-02-25 | -$235.66M derived: sum of 3 quarters · filed 2022-02-25 | -$304.98M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$78.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$133.17M derived: sum of 2 quarters · filed 2022-02-25 | -$202.49M derived: sum of 3 quarters · filed 2022-02-25 | -$266.24M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$54.53M 10-Q · filed 2020-11-05 | -$123.85M derived: sum of 2 quarters · filed 2020-11-05 | -$187.60M 10-Q · filed 2020-11-05 | -$253.19M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$69.32M 10-Q · filed 2020-08-11 | -$133.07M 10-Q · filed 2020-08-11 | -$198.65M derived: sum of 3 quarters · filed 2021-02-25 | -$240.11M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$63.75M 10-Q · filed 2020-05-14 | -$129.34M derived: sum of 2 quarters · filed 2021-02-25 | -$170.79M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | -$65.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$107.04M derived: sum of 2 quarters · filed 2021-02-25 | -$183.66M 10-K · filed 2021-02-25 | |
| 2018-09-30 | -$41.46M 10-Q · filed 2019-11-08 | -$118.08M 10-Q · filed 2019-11-08 | ||
| 2017-12-31 | -$43.86M 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |